CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 40 enrolled
Drug / intervention
Varenicline +1 moredrug
Likely dose
Varenicline 1mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01341080
NCT01341080Phase 2Completed
CompareCT.gov

Varenicline for the Treatment of Postural and Gait Dysfunction in Parkinson Disease

Rush University Medical Center·interventional·Posted Apr 25, 2011·Updated Dec 30, 2022

In Brief

A Phase 2 clinical trial evaluating Varenicline and Sugar pill for Parkinson Disease. Completed, enrolled 40 participants across 1 site.

Detailed Summary

The purpose of this study is to determine if varenicline is effective in improving gait and balance impairment in patients with Parkinson disease.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsParkinson Disease
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedApr 25, 2011
Enrollment StartDec 28, 2010
Primary CompletionNov 2, 2018
TodayJul 2, 2026
Enrollment to primary: 7.8 yearsPosted 15.2 years ago

Interventions

Vareniclinedrug

Varenicline 1mg twice daily for eight weeks after a one week dose escalation period.

Sugar pilldrug

1mg twice daily for eight weeks after a one week dose escalation phase.